Evidence map›Paper›PMID 39760073›Full record

ArticleComputational and structural biotechnology journal2025

Identification of cellular signatures associated with chinese hamster ovary cell adaptation for secretion of antibodies.

Ying Bai, Ivan Domenech Mercadé, Ramy Elgendy, Giulia Lambiase, Sew Peak-Chew, Catarina Franco, Steven W Wingett, Tim J Stevens, Luigi Grassi, Noah Hitchcock and 4 more

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. A Hybrid Modeling Framework for Predictive Digital Twins of CHO Cell Culture.Computational and structural biotechnology journal · 2026
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ying BaiCell Biology Division, Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Ivan Domenech MercadéCell Biology Division, Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Ramy ElgendyTranslational Genomics, Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, Gothenburg, Sweden.
Giulia LambiaseAnalytical Sciences, BioPharmaceutical Development, AstraZeneca, Cambridge, UK.
Sew Peak-ChewCell Biology Division, Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Catarina FrancoCell Biology Division, Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Steven W WingettCell Biology Division, Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Tim J StevensCell Biology Division, Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Luigi GrassiCell Culture and Fermentation Sciences, BioPharmaceutical Development, AstraZeneca, Cambridge UK.
Noah HitchcockCell Culture and Fermentation Sciences, BioPharmaceutical Development, AstraZeneca, Cambridge UK.
Cristina Sayago FerreiraCell Culture and Fermentation Sciences, BioPharmaceutical Development, AstraZeneca, Cambridge UK.
Diane HattonCell Culture and Fermentation Sciences, BioPharmaceutical Development, AstraZeneca, Cambridge UK.
Elizabeth A MillerCell Biology Division, Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Rajesh K MistryCell Culture and Fermentation Sciences, BioPharmaceutical Development, AstraZeneca, Cambridge UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The secretory capacity of Chinese hamster ovary (CHO) cells remains a fundamental bottleneck in the manufacturing of protein-based therapeutics. Unconventional biological drugs with complex structures and processing requirements are particularly problematic. Although engineered vector DNA elements can achieve rapid and high-level therapeutic protein production, a high metabolic and protein folding burden is imposed on the host cell. Cellular adaptations to these conditions include differential gene expression profiles that can in turn influence the productivity and quality control of recombinant proteins. In this study, we used quantitative transcriptomic and proteomic analyses to investigate how biological pathways change with antibody titre. Gene and protein expression profiles of CHO cell pools and clones producing a panel of different monoclonal and bispecific antibodies were analysed during fed-batch production. Antibody-expressing CHO cell pools were heterogeneous, resulting in few discernible genetic signatures. Clonal cell lines derived from these pools, selected for high and low production, yielded a small number of differentially expressed proteins that correlated with productivity and were shared across the biotherapeutics. However, the dominant feature associated with higher protein production was transgene copy number and the resulting mRNA expression level. Moreover, variability between clonal cell lines suggested that the process of cellular adaptation is variable with diverse cellular changes associated with individual adaptation events.

Indexed as

BiotherapeuticsChinese hamster ovary cellsMultiomics

Identifiers

PMID39760073
PMCPMC11697065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.